Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

MLA

Xun Ma, et al. “Daratumumab Binds to Mobilized CD34+ Cells of Myeloma Patients in Vitro without Cytotoxicity or Impaired Progenitor Cell Growth.” Experimental Hematology & Oncology, vol. 7, no. 1, Oct. 2018, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s40164-018-0119-4.

APA

Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga, & Raymond L. Comenzo. (2018). Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Experimental Hematology & Oncology, 7(1), 1–10. https://doi.org/10.1186/s40164-018-0119-4

Chicago

Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, et al. 2018. “Daratumumab Binds to Mobilized CD34+ Cells of Myeloma Patients in Vitro without Cytotoxicity or Impaired Progenitor Cell Growth.” Experimental Hematology & Oncology 7 (1): 1–10. doi:10.1186/s40164-018-0119-4.